Wang Z G, Zhou W Z, Shi J
Jiangsu Provincial Hygiene and Epidemic Prevention Station, Nanjing.
Zhonghua Liu Xing Bing Xue Za Zhi. 1997 Feb;18(1):26-9.
Efficacy and side effects following the immunization with Salmonella typhi Vi capsular polysaccharide vaccine (Vi) were assessed. The diluted solution (DS) of Vi was used as placebo. A total number of 777 children and adults were observed for side effect response. Mild and moderate fever appeared 16.93% and 0.05% in Vi group, 15.01% and 0.03% in DS group, respectively (statistically significant). Two cases with mild local reaction were observed in Vi group. A total number of 81,506 vaccinees were investigated on the efficacy of Vi vaccine, using positive blood culture of Salmonolla typhi as a diagnostic criterion. The protective rate and index of vaccine were 71.35% and 3.49% respectively. If 2 cases of positive Widal's test were included in, the protective rate would come up to 78.17% with a protective index 4.85. Clinical data showed that fever seen in the cases in Vi group was much lower than that of DS group. The systematic and local reaction of Vi vaccine were mild. The vaccine is safe and has high protective rate. It can also decrease the degree of fever with only one single dose as primary immunization. We believe Vi vaccine may serve as a vaccine of new generation to be promoted.
评估了伤寒Vi多糖疫苗(Vi)免疫接种后的效果和副作用。将Vi的稀释溶液(DS)用作安慰剂。共观察了777名儿童和成人的副作用反应。Vi组出现轻度和中度发热的比例分别为16.93%和0.05%,DS组分别为15.01%和0.03%(具有统计学意义)。Vi组观察到2例轻度局部反应。以伤寒杆菌血培养阳性为诊断标准,共调查了81506名接种者的Vi疫苗效果。疫苗的保护率和保护指数分别为71.35%和3.49%。若纳入2例肥达氏试验阳性病例,则保护率可达78.17%,保护指数为4.85。临床资料显示,Vi组病例的发热情况远低于DS组。Vi疫苗的全身和局部反应轻微。该疫苗安全且保护率高。单次接种作为初次免疫即可降低发热程度。我们认为Vi疫苗可作为新一代疫苗推广。